India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Long Island’s commercial real estate market just smashed every previous record, hitting an unprecedented $4.1 billion in 2025 deal volume—up a massive 71.5 percent from the year before. A surge in specialty-use properties like assisted living centers and self-storage facilities fueled the boom, alongside hundreds of new transactions across Nassau and Suffolk counties. With investor confidence rebounding, interest rates easing, and new buyer profiles entering the scene, the region has become one of the hottest real estate markets to watch.
Federal cuts to housing oversight in 2026 are creating a nationwide regulatory scramble, with states—especially California—rapidly stepping in to fill the gap. As the CFPB reduces its enforcement role, lawmakers and agencies across the country are crafting their own rules on mortgage compliance, consumer protection, affordability, and even AI‑driven underwriting. For real estate, mortgage, and finance professionals, the message is clear: state regulations are becoming just as influential as federal policy, making ongoing education and compliance awareness more critical than ever.
The insurance industry poured an eye‑opening $172 million into federal lobbying in 2025, making it the fourth‑largest lobbying sector in the country. Medical insurers led the spending, but property and casualty giants weren’t far behind, with APCIA, Nationwide, Liberty Mutual, and Allstate all landing among the top contributors. And this is only federal spending—state‑level influence, where regulations are truly shaped, remains vastly underreported. For professionals in insurance, real estate, and finance, these lobbying efforts play a powerful role in shaping regulations, costs, and the competitive landscape.
Florida’s home insurance market saw a 3.35% non-renewal rate last year—a small percentage that translated into hundreds of thousands of homeowners suddenly losing coverage. Driven by repeated storm damage, soaring construction costs, heavy litigation, and insurers pulling back from high-risk areas, the state’s insurance landscape is rapidly shifting. Homeowners now face higher premiums, fewer options, and tougher underwriting, while professionals in real estate, mortgage, and insurance must stay informed to guide clients through a tightening market.
Florida’s recent tort reforms are doing far more than reshaping the state’s legal system—they’re driving down property and casualty insurance costs by an average of 14.5% and injecting over $4.2 billion into the state’s economy each year. With nearly 30,000 jobs supported and state and local governments seeing hundreds of millions in new tax revenue, the changes are already transforming Florida’s insurance market. Lawsuits have dropped, insurers are returning, and businesses and homeowners alike are reaping the benefits of a more balanced, competitive, and financially resilient environment.
Major commercial real estate firms are reporting strong revenue and renewed market activity, signaling a rebound in dealmaking and office demand. Yet even with record earnings, CEOs from CBRE, Colliers, and Marcus & Millichap spent much of their earnings calls addressing a growing concern: whether artificial intelligence could threaten traditional brokerage and valuation roles. While leaders insist that complex transactions still rely on human relationships and negotiation, AI‑related market jitters briefly pushed some CRE stocks down before they recovered.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
